vs
Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Incyte (INCY). Click either name above to swap in a different company.
Incyte is the larger business by last-quarter revenue ($1.3B vs $749.2M, roughly 1.7× CLOVER HEALTH INVESTMENTS, CORP.). Incyte runs the higher net margin — 23.8% vs 3.6%, a 20.2% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (62.0% vs 20.9%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (45.0% CAGR vs 10.4%).
Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
CLOV vs INCY — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $749.2M | $1.3B |
| Net Profit | $27.3M | $303.3M |
| Gross Margin | — | — |
| Operating Margin | 3.6% | 23.7% |
| Net Margin | 3.6% | 23.8% |
| Revenue YoY | 62.0% | 20.9% |
| Net Profit YoY | — | 91.7% |
| EPS (diluted) | $0.05 | $1.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $749.2M | $1.3B | ||
| Q4 25 | $487.7M | $1.5B | ||
| Q3 25 | $496.6M | $1.4B | ||
| Q2 25 | $477.6M | $1.2B | ||
| Q1 25 | $462.3M | $1.1B | ||
| Q4 24 | $337.0M | $1.2B | ||
| Q3 24 | $331.0M | $1.1B | ||
| Q2 24 | $356.3M | $1.0B |
| Q1 26 | $27.3M | $303.3M | ||
| Q4 25 | $-49.3M | $299.3M | ||
| Q3 25 | $-24.4M | $424.2M | ||
| Q2 25 | $-10.6M | $405.0M | ||
| Q1 25 | $-1.3M | $158.2M | ||
| Q4 24 | $-22.1M | $201.2M | ||
| Q3 24 | $-9.2M | $106.5M | ||
| Q2 24 | $7.4M | $-444.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 92.0% | ||
| Q3 25 | — | 92.8% | ||
| Q2 25 | — | 93.5% | ||
| Q1 25 | — | 93.0% | ||
| Q4 24 | — | 92.5% | ||
| Q3 24 | 24.5% | 92.4% | ||
| Q2 24 | 30.3% | 92.7% |
| Q1 26 | 3.6% | 23.7% | ||
| Q4 25 | -10.1% | 22.3% | ||
| Q3 25 | -4.9% | 32.5% | ||
| Q2 25 | -2.2% | 43.6% | ||
| Q1 25 | -0.3% | 19.5% | ||
| Q4 24 | -6.4% | 25.6% | ||
| Q3 24 | -2.7% | 12.8% | ||
| Q2 24 | 2.0% | -45.8% |
| Q1 26 | 3.6% | 23.8% | ||
| Q4 25 | -10.1% | 19.9% | ||
| Q3 25 | -4.9% | 31.1% | ||
| Q2 25 | -2.2% | 33.3% | ||
| Q1 25 | -0.3% | 15.0% | ||
| Q4 24 | -6.6% | 17.1% | ||
| Q3 24 | -2.8% | 9.4% | ||
| Q2 24 | 2.1% | -42.6% |
| Q1 26 | $0.05 | $1.47 | ||
| Q4 25 | — | $1.46 | ||
| Q3 25 | — | $2.11 | ||
| Q2 25 | — | $2.04 | ||
| Q1 25 | — | $0.80 | ||
| Q4 24 | — | $0.90 | ||
| Q3 24 | — | $0.54 | ||
| Q2 24 | — | $-2.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.6M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $339.4M | $5.6B |
| Total Assets | $697.7M | $7.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $177.6M | — | ||
| Q4 25 | $78.3M | $3.1B | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.0B | ||
| Q1 25 | — | $1.9B | ||
| Q4 24 | $194.5M | $1.7B | ||
| Q3 24 | $288.0M | $1.3B | ||
| Q2 24 | $254.8M | $987.3M |
| Q1 26 | $339.4M | $5.6B | ||
| Q4 25 | $308.7M | $5.2B | ||
| Q3 25 | $340.9M | $4.7B | ||
| Q2 25 | $344.2M | $4.2B | ||
| Q1 25 | $336.1M | $3.7B | ||
| Q4 24 | $341.1M | $3.4B | ||
| Q3 24 | $342.2M | $3.2B | ||
| Q2 24 | $324.9M | $3.0B |
| Q1 26 | $697.7M | $7.3B | ||
| Q4 25 | $541.0M | $7.0B | ||
| Q3 25 | $559.7M | $6.3B | ||
| Q2 25 | $575.0M | $5.8B | ||
| Q1 25 | $583.7M | $5.7B | ||
| Q4 24 | $580.7M | $5.4B | ||
| Q3 24 | $653.0M | $5.0B | ||
| Q2 24 | $674.2M | $4.7B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
